# 510(k) Summary For The Magellan LeadCar® Ul Bood Lead Testing ystem

# . SUBMITTER/510(k) HOLDER

Magellan Diagnostics, Inc. 101 Billerica Ave, Building 4 North Billerica, MA 01862

Contact Person: Reba Leger Telephone: $+ 1$ (978) 248-4811

AUG 2 0 2013

2 Device Name

Proprietary Name: LeadCare® Ultra™ Blood Lead Testing System   
Common/Usual Name: Lead Test System   
Classification: Class II   
Product Code: DOF   
510(k) Number: k123563

3Predicate Device

LeadCare® 11 Blood Lead Testing System (k052549)

# Device Description

The LeadCare Ultra System Blood Lead Testing System is an in vitro diagnostic device that relies on electrochemistry (Anodic Stripping Voltammetry or ASV) and a unique sensor to detect lead in whole blood. Most lead is carried within red blood cells. When a sample of whole blood is mixed with Treatment Reagent (a dilute solution of hydrochloric acid), the red blood cells are lysed and the lead becomes available for detection. When a test is run, the Analyzer applies an electrical potential that causes the lead to collect on the Sensor. After three minutes, the Analyzer measures the amount of lead on the Sensor and displays the result in micrograms per deciliter $\{ { \mu } \mathbf { g } / \mathbf { d } \mathrm { L } \}$ .

The multi-channel LeadCare Ultra Analyzer performs up to six blood lead tests simultaneously and uploads the completed test results to the Computer. Test results are stored in the Computer in unique sample records, along with sample ID, comments, test conditions, Sensor lot number, and user ID. The Analyzer is also equipped with a Calibration Button Reader. This Reader allows for the download of all calibration information, analytical test parameters, and date code information for any given Sensor lot. These actions can be accomplished by simply touching the appropriate Calibration Button to the Reader.

The system's Computer is dedicated to running only blood lead analyses, and sits on a stand directly behind the monitor. The Computer serves as the user interface for entering patient ID information using a keyboard or barcode reader. It also performs data analysis after blood lead measurements are processed by the firmware embedded in the Analyzer. The Computer stores the patient results (and allows for retrieval of stored results) and it allows connectivity via USB ports to a customersupplied printer and Laboratory Information Management System (LIMS). Peripherals for the computer are a monitor, keyboard, barcode reader and mouse.

The analyzer is used in conjunction with a LeadCare Ultra Blood Lead Test Kit. Materials supplied in the Test Kit include:

Quantity   
Sensors (8 containers of 24 ea.) 192   
• Treatment Reagent Tubes $2 5 0 \mu \mathrm { L }$ of 0.34M HCl) 192   
Calibration Button 1   
Lead Control Level 1 (2mL) 1   
Lead Control Level 2 (2mL) 1

The controls supplied in the Test Kit are manufactured by Bionostics, Inc. to Magellan's specifications. The controls are cleared under K063398.

# 5. Indications for Use/ Intended Use

The LeadCare $^ \mathrm { \textregistered }$ Ultra TM Blood Lead Testing System is designed to quantitatively measure the amount of lead in a whole blood sample. The LeadCare Ultra Blood Lead Testing System is intended for in vitro (external) use only. The test kit components are designed for use only with the LeadCare Ultra Blood Lead Testing System.

This test system is for prescription use only. This system is not intended for point of care use.

6. SUMMARY OF TECHNOLOGICAL CHARACTERISTICS COMPARED TO THE Predicate Device

The following table summarizes the similarities and differences between the predicate and the LeadCare Ultra device.

Similarities/Differences of LeadCare® Ultra™ with Predicate Device   
Page 3 of 10   

<table><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">LeadCareII</td><td colspan="1" rowspan="1">LeadCareUltraTM</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The LeadCare II Blood LeadTesting System is aninstrumented assay to be usedin the quantitation of lead inwhole human blood. TheLeadCare II System is suitablefor use in a Physician's officelaboratory (POL).</td><td colspan="1" rowspan="1">The LeadCare Ultra BloodLead Testing System isdesigned to quantitativelymeasure the amount of lead in awhole blood sample. TheLeadCare Ultra Blood LeadTesting System is intended forin vitro (external) use only. Thetest kit components aredesigned for use only with theLeadCare Ultra Blood LeadTesting System.This test system is forprescription use only. Thissystem is not intended for pointof care use.</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Anodic Stripping Voltammetry</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Throughput</td><td colspan="1" rowspan="1">1 sample at a time</td><td colspan="1" rowspan="1">6 samples at a time</td></tr><tr><td colspan="1" rowspan="1">Sensor (test strip)</td><td colspan="1" rowspan="1">Screen printed sensors withconductive inks; plastic spacerand lid; capillary fill</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Active TestElectrode area</td><td colspan="1" rowspan="1">Thin layer of colloidal gold inan inert polymer matrix</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Electronic calibration button</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Blood Collection</td><td colspan="1" rowspan="1">Fingerstick or venipuncture</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Matrix</td><td colspan="1" rowspan="1">Whole blood collected inEDTA or heparin; fresh up to24 hours from time of draw</td><td colspan="1" rowspan="1">Whole blood collected inEDTA or heparin; up to 72hours from time of draw</td></tr><tr><td colspan="1" rowspan="1">Treatment Reagent</td><td colspan="1" rowspan="1">Dilute hydrochloric acidsolution in water</td><td colspan="1" rowspan="1">Dilute hydrochloric acidsolution in water with inertcarbon particles</td></tr><tr><td colspan="1" rowspan="1">Sample Handling</td><td colspan="1" rowspan="1">Uses transfer dropper totransfer sample from reagenttube to sensor</td><td colspan="1" rowspan="1">Uses pipet to transfer samplefrom reagent tube to sensor</td></tr><tr><td colspan="1" rowspan="1">Check for SensorLot Expiration</td><td colspan="1" rowspan="1">Checks sensor lot expirationdate passed in on the calibrationbutton</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Internal Self-Test</td><td colspan="1" rowspan="1">Self-test checks electronicfunctions of analyzer each timeit is turned ON</td><td colspan="1" rowspan="1">Self-test checks electronicfunctions of analyzer each timeit is turned ON and on eachchannel following a sensorinsertion</td></tr><tr><td colspan="1" rowspan="1">Sensor Connector</td><td colspan="1" rowspan="1">Makes electrical contact withsensor. Sensor insertiondetection.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Unit of Measure</td><td colspan="1" rowspan="1">Results displayed inmicrograms of lead per deciliterof whole blood (μg/dL)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Displayed Result</td><td colspan="1" rowspan="1">Lead result is displayed untilnew sensor is inserted</td><td colspan="1" rowspan="1">Lead results displayed via UserInterface and stored incomputer</td></tr><tr><td colspan="1" rowspan="1">Reportable Range</td><td colspan="1" rowspan="1">3.3-65 μg/dL</td><td colspan="1" rowspan="1">1.9-65 μg/dL</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">2 levels of external liquidcontrols</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Power Source</td><td colspan="1" rowspan="1">AC Adapter or 4 AA batteries</td><td colspan="1" rowspan="1">AC Adapter</td></tr><tr><td colspan="1" rowspan="1">Test Time</td><td colspan="1" rowspan="1">3 minutes</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Software</td><td colspan="1" rowspan="1">Software is in the form offirmware only, installed ontothe analyzer's microprocessor.All functions (analyzer control,User Interface display control,blood lead algorithmcalculation) are executed bythis firmware</td><td colspan="1" rowspan="1">Software is in the form offirmware installed onto theanalyzer's microprocessor, and.NET based software installedonto an accompanyingcomputer workstation withWindows 7 Embedded POSReady operating system.The firmware is used for thelow level control of theanalyzer only. The software onthe computer workstation isused to run the system UserInterface software and performthe blood lead algorithmcalculations, receiving raw datafrom the firmware</td></tr><tr><td colspan="1" rowspan="1">Lead Test Algorithm</td><td colspan="1" rowspan="1">ASV routine; Pb peak identifiedand quantified; blood Pb resultassigned using lookup tables</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">User Interface</td><td colspan="1" rowspan="1">Alphanumeric display, 4 linesby 20 characters allows usefulmessages to guide usersthrough procedure</td><td colspan="1" rowspan="1">Graphical user interface withmessages and graphics to guideusers through procedure</td></tr><tr><td>System Operating Range</td><td>Temperature range of 54° to 97°F (12° to 36°C); Relative Humidity 12%-80% non- condensing to accommodate</td><td>Temperature range of 60° to 82°F (16° to 28°C); Relative Humidity 12%-80% non- condensing to accommodate</td></tr><tr><td>Limit of Detection</td><td>field portability 3.3 μg/dL</td><td>typical laboratory use 1.9 μg/dL</td></tr></table>

# 7. Summary Of Non-CLiniCAl And CLiniCal Performance TEsting As BasiS For Substantial Equivalence

# A. Non-Clinical Results

# Precision

The LeadCare Ultra Precision Study was performed using bovine blood standards at lead concentrations of 4.5, 6.4, 10.8, 24.4, 44.2, and $6 2 . 1 ~ \mu \mathrm { g / d L }$ . Eighty (80) data points were collected per concentration level over a 20 day period. Samples were prepped two times per day and each sample was run in duplicate on alternating channels such that all channels were used equally during the study. For concentrations of 4.5, 6.4 and $6 2 . 1 ~ \mu \mathrm { g / d L }$ , three sensor lots were utilized. For the remaining concentrations, one representative sensor lot was used. The combined data set is shown.

LeadCare Ultra Precision Data   

<table><tr><td rowspan=1 colspan=1>Mean,jg/dL</td><td rowspan=1 colspan=1>WRSD,μg/dL</td><td rowspan=1 colspan=1>TotalSD,μg/dL</td><td rowspan=1 colspan=1>WRCV</td><td rowspan=1 colspan=1>TotalCV</td><td rowspan=1 colspan=1>95%CI forWR SD,μg/dL</td><td rowspan=1 colspan=1>95%CI forTotal SD,μg/dL</td></tr><tr><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>10.9%</td><td rowspan=1 colspan=1>0.32 to 0.42</td><td rowspan=1 colspan=1>0.45 to 0.55</td></tr><tr><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>0.55</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>8.7%</td><td rowspan=1 colspan=1>9.4%</td><td rowspan=1 colspan=1>0.49 to 0.63</td><td rowspan=1 colspan=1>0.55 to 0.67</td></tr><tr><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>8.3%</td><td rowspan=1 colspan=1>0.65 to1.03</td><td rowspan=1 colspan=1>0.78 to 1.08</td></tr><tr><td rowspan=1 colspan=1>24.4</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>1.43</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>0.99to1.54</td><td rowspan=1 colspan=1>1.22 to 1.73</td></tr><tr><td rowspan=1 colspan=1>44.2</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>1.62</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>1.28 to 1.99</td><td rowspan=1 colspan=1>1.40 to 1.93</td></tr><tr><td rowspan=1 colspan=1>62.1</td><td rowspan=1 colspan=1>1.90</td><td rowspan=1 colspan=1>3.19</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>1.69 to 2.18</td><td rowspan=1 colspan=1>2.91 to 3.54</td></tr></table>

# Magellan DIAGNOSTICS

# Linearity

Linearity assessments were performed on three Sensor lots using nine donor blood samples spiked with lead to concentrations of $2 { - } 5 ~ { \mu } \mathrm { g } / \mathrm { d L }$ , $5 { \cdot } 1 0 ~ \mu \varrho / \mathrm { d L }$ , $1 5 { \cdot } 2 5 ~ { \mu } \mathrm { g } / \mathrm { d L } ,$ . $2 5 { \scriptstyle - 3 5 } { \scriptstyle \mu \mathrm { g } } / \mathrm { d L }$ , $3 5 { \cdot } 4 5 ~ \mu \mathrm { g / d L }$ $4 5 { - } 5 5 ~ \mu \mathrm { g / d L }$ & $5 5 { \cdot } 6 5 ~ \mu \mathrm { g / d L }$ . The concentrations used span the claimed measuring range of the LeadCare Ultra System. Linearity was evaluated by performing polynomial regression and determining whether higher order coefficients were statistically significant as per CLSI EP6-A Section 5.32.

The Linear Regression results for each of the three Sensor lots are as follows:

1208A EY $\begin{array} { r } { \mathbf { Y } = 1 . 0 4 \mathbf { x } - 1 . 1 7 } \end{array}$ $\mathbb { R } ^ { 2 } = 0 . 9 9 7$ EY $\mathbf { S y . x } = 1 . 4 1$

$$
\begin{array} { l } { \frac { 1 2 1 1 \mathrm { B } } { \mathrm { Y } = 1 . 1 0 \mathrm { x } - 1 . 7 1 } } \\ { \mathrm { R } ^ { 2 } = 0 . 9 9 6 } \\ { \mathrm { S y . x } = 1 . 6 4 } \end{array}
$$

$$
\begin{array} { r l } & { \frac { 1 3 0 5 \mathsf { A } } { \mathsf { Y } = 1 . 0 4 \mathsf { x } - 0 . 5 8 } } \\ & { \mathsf { R } ^ { 2 } = 0 . 9 9 8 } \\ & { \mathsf { S y } . \mathsf { x } = 1 . 0 5 } \end{array}
$$

For each of the three lots, the average of the LeadCare Ultra replicates was analyzed against the average reference method (GFAAS) results using polynomial regression analysis. The (p) values for the higher order coefficients of the polynomial regressions were calculated for three lots of Sensors. All p values were greater than 0.05, demonstrating no statistically significant nonlinearity for the range 1 - 66 $\mu \mathbf { g } / \mathbf { d L }$ .

Random error was evaluated by estimating precision from replicates. These precision data met the precision goals.

Analysis of samples from $1 . 9 ~ \mu \ g / \mathrm { d L }$ to $6 5 \mu \mathrm { g / d L }$ was performed to demonstrate linearity across the claimed measuring range. Quadratic and Cubic regression results are shown in the table below:

Quadratic and Cubic Regression Data (range 1.9 μg/dL  65 μg/dL)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>QuadraticRegression</td><td rowspan=1 colspan=2>Cubic Regression</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Quad Coefficient</td><td rowspan=1 colspan=1>Quad Coefficient</td><td rowspan=1 colspan=1>Cubic Coefficient</td></tr><tr><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>p value</td><td rowspan=1 colspan=1>p value</td><td rowspan=1 colspan=1>p value</td></tr><tr><td rowspan=1 colspan=1>1208A</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>0.27</td></tr><tr><td rowspan=1 colspan=1>1211B</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.58</td></tr><tr><td rowspan=1 colspan=1>1305A</td><td rowspan=1 colspan=1>0.69</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.20</td></tr></table>

The LeadCare Ultra system demonstrated linearity for three lots across the claimed analytical range of $1 . 9 { \cdot } 6 5 ~ { \mu } \mathrm { g } / \mathrm { d L }$ .

Linearity was also demonstrated for each of the six channels on the LeadCare Ultra analyzer. Replicate data on each channel met precision goals.

# Limit of Blank, Limit of Detection & Limit of Quantification

The limit of blank LoB was determined by running 70 replicates of a near blank NIST blood sample, $0 . 3 ~ \mu \mathrm { g / d L }$ , over 5 days. Samples were analyzed using two Sensor lots across all Analyzer channels.

The LoB was calculated to be $1 . 5 ~ \mu \varrho / \mathrm { d L }$ .

Replicates of the low samples were run on the LeadCare Ultra Analyzer over five days. Seventy (70) data points were collected using all channels of the Analyzer. Two Sensor lots were used.

The LoD was calculated to be $1 . 9 \mu \mathrm { g / d L }$ .

The limit of quantification LoQ was calculated using the Total Error equation: Total Error $\mathrm { L o Q } =$ absolute $( { \bf B i a s } ) + ( 2 { \bf x } { \bf S D } )$ .The bias of 58 samples that contained lead concentrations between 1 and $6 \mu \mathrm { g } / \mathrm { d L }$ , according to GFAAS, was calculated to be $0 . 0 2 \mu \mathrm { g } / \mathrm { d L }$ .

The Standard Deviation at the LoD $( 1 . 9 \mu \mathrm { g } / \mathrm { d L } )$ is calculated to be $0 . 2 5 ~ \mu \mathrm { g } / \mathrm { d L }$ Based on the equation above, the Total Error LoQ is calculated to be:

Total Error $\mathrm { L o Q } = 0 . 0 2 + ( 2 \times 0 . 2 5 )$ EY Total Error $\mathrm { L o Q } = 0 . 5 2$ EPY

The LoQ is equal to the LoD $( 1 . 9 \mu \mathrm { g } / \mathrm { d L } )$ .

# Matrix Comparison

Matrix Comparisons were made for the following blood collection devices:

√ $\mathbf { K } _ { 3 } \mathbf { E D T A }$ , $\mathbf { K } _ { 2 } \mathbf { E D T A }$ Vacutainers • Sodium Heparin Vacutainers Micro-capillary tubes with $\mathbf { K } _ { 2 } \mathbf { E D T A }$

Linear Regression Results of LeadCare Ultra compared to GFAAS met the acceptance criteria, defined as average bias within $\pm 2 \ \mu \mathrm { g / d L }$ in the concentration range 1.9 to $1 0 ~ { \mu \mathbf { g } } / { \ d \mathrm { L } }$ and $\pm 1 0 \%$ for concentrations above $1 0 ~ \mu \mathrm { g / d L }$ .

Micro-capillary tubes with $\mathbf { K } _ { 2 } \mathbf { E D T A }$ $_ { ( N = 7 2 }$ tubes)   

<table><tr><td rowspan=1 colspan=1>GFAAS,μg/dL</td><td rowspan=1 colspan=1>PredictedUltraμg/dL</td><td rowspan=1 colspan=1>Bias,µg/dL</td><td rowspan=1 colspan=1>PercentBias</td></tr><tr><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>-0.2</td><td rowspan=1 colspan=1>-10.3%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>-0.6%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20.8</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>31.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>4.4%</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>41.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>4.6%</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>52.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>62.9</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>4.9%</td></tr><tr><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>68.2</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>4.9%</td></tr></table>

K3EDTA, ${ \bf K } _ { 2 } { \bf E } { \bf D } { \bf T } { \bf A }$ and Sodium Heparin Vacutainers $\scriptstyle \mathbf { N } = 3 9$ vacutainers each)   

<table><tr><td rowspan=1 colspan=1>GFAAS</td><td rowspan=1 colspan=2>Calculated EDTA Bias</td><td rowspan=1 colspan=2>Calculated Heparin Bias</td></tr><tr><td rowspan=1 colspan=1>μg/dL</td><td rowspan=1 colspan=1>µg/dL</td><td rowspan=1 colspan=1>PercentBias</td><td rowspan=1 colspan=1>µg/dL</td><td rowspan=1 colspan=1>Percent Bias</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-0.02</td><td rowspan=1 colspan=1>---</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>---</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>-0.05</td><td rowspan=1 colspan=1>-1.02%</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>3.20%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>-0.08</td><td rowspan=1 colspan=1>-0.80%</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>2.93%</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>-0.11</td><td rowspan=1 colspan=1>-0.72%</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>2.84%</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>-0.14</td><td rowspan=1 colspan=1>-0.69%</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>2.80%</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>-0.17</td><td rowspan=1 colspan=1>-0.67%</td><td rowspan=1 colspan=1>0.69</td><td rowspan=1 colspan=1>2.77%</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>-0.20</td><td rowspan=1 colspan=1>-0.65%</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>2.75%</td></tr><tr><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>-0.22</td><td rowspan=1 colspan=1>-0.64%</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>2.74%</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>-0.25</td><td rowspan=1 colspan=1>-0.63%</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>2.73%</td></tr><tr><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>-0.28</td><td rowspan=1 colspan=1>-0.63%</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>2.72%</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>-0.31</td><td rowspan=1 colspan=1>-0.62%</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>2.72%</td></tr><tr><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>-0.34</td><td rowspan=1 colspan=1>-0.62%</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>2.71%</td></tr><tr><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>-0.37</td><td rowspan=1 colspan=1>-0.61%</td><td rowspan=1 colspan=1>1.63</td><td rowspan=1 colspan=1>2.71%</td></tr></table>

# Sensor Lot Calibration and Traceability

Calibration of sensor lots, traceable to NIST Standard Reference Material 955c (Lead in Caprine Blood) is performed using four concentrations of control samples. The control samples are used to calibrate a GFAAS instrument, used for comparison with the LeadCare Ultra system. As part of the calibration, blood samples spiked at 8 concentrations are analyzed by both the LeadCare Ultra system and GFAAS, run in duplicate on 2 separate days.

# B. Clinical Results

# Method Comparison

The LeadCare Ultra method comparison study was conducted at two sites. Samples collected in EDTA vacutainers, were run in duplicate on GFAAS, the reference method and once on the LeadCare Ultra system. Three hundred ninety four (394) results were generated and 148 were within the claimed analytical range of 1.9-65 $\mu \mathrm { g } / \mathrm { d L }$ .

The average of the two GFAAS results was plotted against the LeadCare Ultra result for each sample. Regression analysis for the 148 results is presented.

LeadCare Ultra Results vs. GFAAS average. $( \mathrm { R } ^ { 2 } = 0 . 9 7 8$ . $\mathrm { N } { = } 1 4 8$ data points).

![](images/ef4439d56f8ce62368c7a67fbba2fb5c4a783838f1eeafc9870d0d4361634371.jpg)

The predicted bias for various lead concentrations (LeadCare Ultra) across the analytical range are shown below:

LeadCare Ultra Average Bias from GFAAS   

<table><tr><td rowspan=1 colspan=1>GFAAS,μg/dL</td><td rowspan=1 colspan=1>PredictedUltra, μg/dL</td><td rowspan=1 colspan=1>AverageBias,μg/dL</td><td rowspan=1 colspan=1>PercentBias</td></tr><tr><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.2%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>-0.04</td><td rowspan=1 colspan=1>-0.4%</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19.9</td><td rowspan=1 colspan=1>-0.15</td><td rowspan=1 colspan=1>-0.7%</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>29.7</td><td rowspan=1 colspan=1>-0.26</td><td rowspan=1 colspan=1>-0.9%</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>39.6</td><td rowspan=1 colspan=1>-0.36</td><td rowspan=1 colspan=1>-0.9%</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>49.5</td><td rowspan=1 colspan=1>-0.47</td><td rowspan=1 colspan=1>-0.9%</td></tr><tr><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>59.4</td><td rowspan=1 colspan=1>-0.58</td><td rowspan=1 colspan=1>-1.0%</td></tr><tr><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>64.4</td><td rowspan=1 colspan=1>-0.63</td><td rowspan=1 colspan=1>-1.0%</td></tr></table>

The clinical data met the acceptance criteria, defined as average bias within the range of $\pm 2 \ \mu \mathrm { g / d L }$ in the concentration range 1.9 to $1 0 ~ \mu \varrho / \mathrm { d L }$ and $\pm 1 0 \%$ for concentrations above $1 0 ~ { \mu \mathrm { g / d L } }$ .

# 8. Summary Of Other Information

This submission included a comparison of intended use statements, proposed product labeling, environmental testing and software validation.

# 9. Conclusions Drawn from Non-Clinical and Clinical Tests

Based on the information provided in this $5 1 0 ( \mathbf { k } )$ , Magellan believes that the proposed LeadCare Ultra Application is substantially equivalent to the previously cleared predicate product. The proposed device raises no new issues of safety and effectiveness. The non-clinical and clinical testing performed demonstrates that the proposed device met all the specifications and is suitable for its intended use.

# August 20, 2013

Magellan Diagnostics, Inc. C/O Stuart Naylor 101 Billerica Ave, Building 4 NORTH BILLERICA MA 01862-1271

Re: K123563 Trade/Device Name: LeadCare® Ultra™ Blood Lead Testing System Regulation Number: 21 CFR 862.3550 Regulation Name: Lead test system Regulatory Class: II Product Code: DOF Dated: July 10, 2013 Received: July 11, 2013

Dear Stuart Naylor:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucml15809.htm for

the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Carol C. Benson -S for

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K123563

Device Name: LeadCare Ultra Blood Lead Testing System

Indications for Use:

The LeadCare $\textsuperscript { \textregistered }$ Ultra TM Blood Lead Testing System is designed to quantitatively measure the amount of lead in a whole blood sample. The LeadCare $^ { \textregistered }$ Ultra TM Blood Lead Testing System is intended for in vitro (external) use only. The test kit components are designed for use only with the LeadCare $\textcircled{8}$ Ultra TM Blood Lead Testing System.

This test system is for prescription use only.This system is not intended for point of care use.

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

# Ruth A. Chesler -S

Division Sign-Off Office of In Vitro Diagnostics and Radiological Health